Press Releases Events & Presentations Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Aug 13, 2026 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates View HTML PDF Version May 28, 2026 Assembly Biosciences Announces Upcoming Investor Conference Presentations View HTML PDF Version May 26, 2026 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases View HTML PDF Version May 13, 2026 Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 View HTML PDF Version May 11, 2026 Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference View HTML PDF Version May 07, 2026 Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights View HTML PDF Version Apr 09, 2026 Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 View HTML PDF Version Mar 19, 2026 Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights View HTML PDF Version Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Aug 13, 2026 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates View HTML PDF Version May 28, 2026 Assembly Biosciences Announces Upcoming Investor Conference Presentations View HTML PDF Version May 26, 2026 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases View HTML PDF Version May 13, 2026 Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 View HTML PDF Version May 11, 2026 Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference View HTML PDF Version May 07, 2026 Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights View HTML PDF Version Apr 09, 2026 Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 View HTML PDF Version Mar 19, 2026 Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights View HTML PDF Version
